Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$128.91 USD
+0.68 (0.53%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $128.84 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Neurocrine Biosciences, Inc. has a PEG ratio of 1.47 compared to the Medical - Drugs industry's PEG ratio of 1.32.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NBIX 128.91 +0.68(0.53%)
Will NBIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
CPRX vs. NBIX: Which Stock Should Value Investors Buy Now?
Indivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for NBIX
Neurocrine (NBIX) Receives Upgraded Price Target After Strong Earnings
Guggenheim Raises Price Target for NBIX, Maintains "Buy" Rating | NBIX Stock News
Neurocrine price target raised by $10 at Guggenheim, here's why
NBIX: RBC Capital Maintains Rating but Lowers Price Target | NBIX Stock News
NBIX: Stifel Raises Price Target to $174, Reiterates Buy Rating | NBIX Stock News